PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
Abstract Advanced hepatocellular carcinoma (HCC) is characterized by poor prognosis, primarily due to limited therapeutic options and resistance to treatment. Although the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has shown promising potential, the unde...
Saved in:
| Main Authors: | Jitong Zhou, Meng Gao, Shikun Zhang, Wing‐Wa Guo, Wenzhi He, Minghe Zhang, Xi Chen, Cairang Dongzhi, Xiaomian Li, Yufeng Yuan, Weijie Ma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202501730 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis
by: Wei Zhang, et al.
Published: (2025-05-01) -
Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
by: JIANG Jiayun, et al.
Published: (2024-11-01) -
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01) -
Mono‐TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study
by: Xue Yin, et al.
Published: (2025-03-01) -
Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01)